Reports Q4 revenue $22.418M, consensus $20.82M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
- Optinose downgraded to Neutral from Buy at H.C. Wainwright
- Optinose downgraded to Neutral from Overweight at Piper Sandler
- Hold Rating Issued Amid Optinose Acquisition by Paratek Pharmaceuticals with Adjusted Price Target
- Optinose downgraded to Hold from Buy at Lake Street
- Paratek Pharmaceuticals to acquire Optinose in $330M transaction